Darolutamide submitted for marketing authorization in Japan

NEXT STORY
Novartis Cosentyx® shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara®*
PREV STORY
Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Ischemic Events
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OV – Update Regarding Participation at Investor Events in Q4 2018

Investor news  Hørsholm, Denmark and Cambridge, MA, US, November 5th, 2018 - Oncology Venture ...

author_avatar
NASDAQ Market News

TESARO Announces Second-Quarter 2017 Operating Results

ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 ...

author_avatar
NASDAQ Market News

Agios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017

CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader ...

author_avatar
NASDAQ Market News